Related Experiment Video
Updated: Mar 5, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
21.2K
High Dose Rate Brachytherapy as Monotherapy for Localised Prostate Cancer: Review of the Current Status
N Tselis1, P Hoskin2, D Baltas3
1Department of Radiotherapy and Oncology, University Hospital, Goethe University of Frankfurt, Frankfurt am Main, Germany.
Clinical Oncology (Royal College of Radiologists (Great Britain))
|March 26, 2017
Summary
High dose rate (HDR) brachytherapy as monotherapy offers excellent biochemical control and low toxicity for localized prostate cancer. This review confirms its safety and efficacy for organ-confined disease.
Area of Science:
- Oncology
- Radiation Oncology
- Urology
Background:
- Prostate cancer is a leading diagnosis in men globally.
- High dose rate (HDR) brachytherapy is an evolving treatment modality.
- Monotherapy approaches are increasingly investigated for localized prostate cancer.
Purpose of the Study:
- To review and present published data on high dose rate (HDR) brachytherapy used as monotherapy for localized prostate cancer.
- To evaluate oncological outcomes and toxicity profiles of HDR brachytherapy monotherapy.
Main Methods:
- Comprehensive literature search of PubMed and MedLine databases (2000-2016).
- Inclusion of original clinical data on HDR monotherapy with oncological outcomes.
- Analysis of 15 articles reporting on 3546 patients with follow-up from 1.4 to 8.0 years.
Main Results:
- Biochemical control rates varied by risk group: 66-100% (low), 63-98% (intermediate), and 81-93% (high).
- Late grade 3 genitourinary toxicity was 0-16%, and gastrointestinal toxicity was 0-2%.
- Potency preservation rates ranged from 60-90%.
Conclusions:
- HDR brachytherapy monotherapy demonstrates high rates of biochemical control for localized prostate cancer.
- The treatment is associated with low rates of severe genitourinary and gastrointestinal toxicity.
- HDR brachytherapy is a safe, effective, and reproducible local treatment for organ-confined prostate cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K